¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chronic monocytic leukaemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸¹éÇ÷º´
  • chronic myelocytic leukemia
    ¸¸¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • chronic myeloproliferative disorder
    ¸¸¼º°ñ¼öÁõ½ÄÁúȯ
  • chronic obstructive pulmonary disease
    ¸¸¼ºÆó¼âÆóÁúȯ
  • chronic pain syndrome
    ¸¸¼ºÅëÁõÁõÈıº
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • chronic progressive disciform granulomatosis
    ¸¸¼ºÁøÇà¿ø¹ÝÀ°¾ÆÁ¾Áõ
  • chronic relapsing pancreatitis
    ¸¸¼ºÀç¹ßÀÌÀÚ¿°, ¸¸¼ºÀç¹ßÃéÀå¿°
  • chronic renal failure
    ¸¸¼ºÄáÆÏ±â´É»ó½Ç, ¸¸¼º½ÅºÎÀü
  • chronic vasomotor instability
    ¸¸¼ºÇ÷°ü¿îµ¿ºÒ¾ÈÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic vasomotor instability
    ¸¸¼ºÇ÷°ü¿îµ¿ºÒ¾ÈÁ¤
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bronchitis, chronic
    ±â°üÁö¿°(¡­æú), ¸¸¼º(Ø·àõ)
  • carrier, chronic
    ¸¸¼ºº¸±ÕÀÚ
  • chronic
    ¸¸¼ºÀÇ
  • chronic acholuric jaundice
    ¸¸¼º¹«´ã»ö¼Ò´¢¼º Ȳ´Þ(¡­ÙíÓÅßäáÈèñàõüÜÓ¸).
  • chronic acholuric jaundice
    ¸¸¼º¹«´ã»ö¼Ò´¢¼º Ȳ´Þ(¡­ÙíÓÅßäáÈèñàõüÜÓ¸)
  • chronic acral dermatitis
    ¸¸¼º ¸»´Ü ÇǺο°
  • chronic actinic changes
    ¸¸¼º(´ÜÆÄ)±¤¼±¼º º¯È­(Ø·àõÓ­÷îÎÃàÊàõܨûù).
  • chronic actinic dermatitis
    ¸¸¼º ±¤¼± ÇǺο°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿¼º °£¿°(¡­ÊÜæú).
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic administration
    ¸¸¼ºÅõ¿©.
  • chronic ambulatory peritoneal dialysis
    Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®
  • chronic arterial occlusion
    ¸¸¼ºµ¿¸ÆÆó¼â.
  • chronic atrophic gastritis
    ¸¸¼ºÀ§Ã༺ À§¿°(¡­ê×õêàõêÖæú).
  • chronic atrophic laryngitis
    ¸¸¼ºÀ§Ãà(¼º)Èĵο°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AML acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem...
MLA left mentoanterior [fetal position] [Lat. mento-laeva anterior]; Medical Library Association; mesiol...
CPH Certificate in Public Health; chronic paroxysmal hemicrania; chronic persistent hepatitis; chronic p...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
CAH chronic active hepatitis; chronic aggressive hepatitis; combined atrial hypertrophy; congenital adre...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
B CLL B chronic lymphocytic leukaemia
B-CLL B type chronic lymphocytic leukaemia
CLL Chronic Lymphatic Leukaemia
CLL B-chronic lymphocytic leukaemia
CML Chronic Myelogenous Leukaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chronic closed angle glaucoma
    ¸¸¼º Æó¼â°¢ ³ì³»Àå
  • chronic conjunctivitis
    ¸¸¼º °á¸·¿°
  • chronic cystic mastitis
    ¸¸¼º ³¶¼º À¯¹æ¿°
  • chronic dacryocystitis
    ¸¸¼º ´«¹° ÁÖ¸Ó´Ï ¿°Áõ, ¸¸¼º ´©³¶¿°
  • chronic dermatitis
    ¸¸¼º ÇǺο°
  • chronic diffuse sclerosing osteomyelitis
    ¸¸¼º ¹Ì¸¸¼º °æÈ­¼º °ñ¼ö¿°
    ¹Ì¸¸¼ºÀÇ Ä¡ÃßÁúȯ¿¡ ÀÇÇÑ °¨¿°¿¡¼­ ºñ·ÔµÈ´Ù. ³·Àº Á¤µµÀÇ °¨¿°¿¡ ´ëÇÑ °ñÀÇ Áõ½Ä¼º ¹ÝÀÀÀÌ´Ù. ³ë³âÃþÀÇ ¹«Ä¡¾Ç ºÎÀ§¿¡ ÁÖ·Î »ý±ä´Ù. Ưº°ÇÑ ¼Ò°ßÀº ¾ø´Ù. °ñÀÇ ¹Ì¸¸¼º °æÈ­°¡ ½ÉÇÏ°í ¾çÃø¼ºÀÌ´Ù. °æ°è´Â ºÒ¸í·áÇÏ´Ù. Á¶Á÷º´¸®ÇÐÀû ¼Ò°ßÀº Á¶¹ÐÇÏ°í ºÒ±ÔÄ¢ÇÑ °ñ¼ö, ¼¶À¯¼º °ñ¼ö°­ÀÌ´Ù.
  • chronic disease
    ¸¸¼º Áúȯ
    º´ÀÇ °æ°úÀÇ Àå´Ü¿¡ ÀÇÇÑ ºÐ·ù. º¸Åë 6°³¿ù ȤÀº l³â ÀÌ»ó °è¼ÓµÇ´Â ÁúȯÀ» ¸»Çϸç, ±Þ¼º Áúȯ°ú ´ëÀÀÇÑ´Ù. ±× Áõ¼¼°¡ ¿Ï¸¸ÇÏ°Ô ³ªÅ¸³ª Àå±â°£ Áö¼ÓÇϹǷΠ¸¸¼º Áõ»óÀ̶ó Çϸç, À̰͵µ ±Þ¼º Áúȯ¿¡¼­ÀÇ ±Þ¼º Áõ»ó¿¡ ´ëÀÀÇÏ´Â ¸»ÀÌ´Ù. ´ëÇ¥ÀûÀÎ ¸¸¼º ÁúÇÑÀ¸·Î´Â °áÇÙ, ³ªº´, ¸Åµ¶ µîÀÌ ÀÖ°í, ±Þ¼º Áúȯ¿¡¼­ ÀÌÇàÇÏ´Â °Íµµ ¸¹´Ù. ´Ü¼øÈ÷ ¾ËÄÚ¿Ã Áßµ¶À̳ª °üÀý ·ù¸ÓƼÁò µîÀÇ °æ¿ì´Â ¸¸¼ºÀ¸·Î º¸´Â °æ¿ì°¡ ¸¹´Ù.
  • chronic empyema
    ¸¸¼º ³óÈä
  • chronic endemic dental fluorosis
    ¸¸¼º À¯Ç༺ Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ, ¸¸¼º dzÅ伺 Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ
  • chronic erythematous atrophic candidosis
    ¸¸¼º È«¹Ý¼º À§Ã༺ ĵµð´ÙÁõ
  • chronic exposure
    ¸¸¼º ³ëÃâ
  • chronic factitious disorder with physical symptom
    ¸¸¼º ÀΰøÀû Àå¾Ö ½ÅüÀû
  • chronic fatigue syndrome
    ¸¸¼º ÇÇ·Î ÁõÈıº
    ½±°Ô ÇǰïÇϰí ÁöÄ¡¸ç ¸öÀÌ ³ª¸¥ÇØÁö´Â µîÀÇ ÇÇ·Î Áõ¼¼°¡ 6°³¿ù ÀÌ»ó ¸¸¼ºÀûÀ¸·Î Áö¼ÓÇÏ´Â Áõ»ó. È®½ÇÇÑ ¿øÀÎÀº ¹àÇôÁ® ÀÖÁö ¾Ê°í, ¹ÙÀÌ·¯½º °¨¿°ÀÌ ±× ¿øÀÎÀÇ Çϳª·Î ÃßÁ¤µÈ´Ù. Æò¼Ò °Ç°­ÇÑ »ç¶÷¿¡°Ô¼­ °¨±â³ª ¸ö»ì ±â¿îÀÌ ÀÖ´Ù°¡ ÀÌ·± ÇǷΰ¡ ³ªÅ¸³­´Ù. ´ëü·Î Ưº°ÇÑ Ä¡·á°¡ ÇÊ¿ä¾øÀÌ ÀúÀý·Î Ä¡À¯µÇ³ª ÇǷθ¦ ´À³¢°Ô ÇÏ´Â ´Ù¸¥ Áúº´ÀÇ À¯¹«¸¦ È®ÀÎÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. ƯÈ÷ ½ºÆ®·¹½º, ¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö µî°ú °°Àº Á¤½ÅÀû ¹®Á¦°¡ ¾à 50 %¸¦ Â÷ÁöÇϸç, ½ÅüÀû ÁúȯÀ¸·Î´Â ´ç´¢º´, °©»ó¼± Áúȯ, ¸¸¼º È£Èí±â Áúȯ, ºóÇ÷, °áÇÙ, °£¿°, ½ÅÀå ÁúȯÀ̳ª ¾Ï µî¿¡ ÀÇÇØ¼­µµ ¸¸¼ºÀû ÇǷΰ¨À» ´À³¥ ¼ö ÀÖ´Ù. ÀÌ¿Í °°Àº ÁúȯÀÌ ¾ø´Â °ÍÀÌ ÆÇ¸íµÇ¸é ¸¸¼º ÇÇ·Î ÁõÈıºÀ¸·Î Áø´ÜÇÒ ¼ö ÀÖ´Ù.
  • chronic flying sickness
    ¸¸¼º Ç×°øº´
    Àå±â°£ Ç×°ø±â¿¡ ž½ÂÇÏ´Â »ç¶÷¿¡°Ô ÀϾ´Â Á÷¾÷º´. Ç×°ø±âÀÇ ²÷ÀÓ¾ø´Â µ¿¿ä, ¼±È¸, °¡¼Óµµ, °í°ø ºñÇàÀ¸·ÎºÎÅÍ ¿À´Â »ê¼ÒÀÇ ºÎÁ·, ±â¾ÐÀÌ ³·Àº °í°øÀ» ºñÇàÇϰųª Àú¾Ð½Ç¿¡¼­ ÀÛ¾÷À» ÇÏ´Â °æ¿ì, ±×°ÍÀ¸·Î ±Þ¼º ÁúȯÀÌ ÀϾÁö ¾Ê´Â Á¤µµÀÇ È¯°æÀÌ Àå±â°£¿¡ °ÉÃļ­ µÇÇ®ÀÌµÉ ¶§ ¹ß»ýÇϱ⠽±´Ù. Áõ¼¼´Â Ãʱ⿡ ´«ÀÇ ÇÇ·Î, µÎÅë, ÇǷΰ¨ µîÀÇ ÀÚ°¢ Áõ¼¼°¡ ÀϾ°í, ÀÌ¿Í °°Àº ´Ü°è°¡ Áö³ª¸é ÃÊÁ¶°¨, ½Å°æÁú, ºÒ¸éÁõ, ±â¾ï·Â, ÁýÁß·ÂÀÇ °¨Åð¿Í ÇÔ²² ±¸Åä, Çö±âÁõ, ¼ÒÈ­ºÒ·® µîÀÌ ÀϾ´Ù. À̰ÍÀº °í°ø ºñÇàÀ̳ª, ¼Óµµ°¡ ºü¸£°í ¼±È¸°¡ ½ÉÇÑ ÀüÅõ±â¸¦ Á¶Á¾ÇÏ´Â ÀüÅõ Á¶Á¾»ç¿¡°Ô ¹ß»ýµÇ´Â °æ¿ì°¡ ¸¹´Ù.
  • chronic gingivitis
    ¸¸¼º Ä¡Àº¿°
    1. º¯¿¬ Ä¡ÀºÀÇ ºÎÁ¾, ÃâÇ÷À» º¸ÀδÙ. È­³ó¼ºÀ̸ç, Ä¡ÀºÀÇ Á¡¸ôÀÌ ¼Ò½ÇµÈ´Ù. ±¹¼ÒÀûÀÌ ¿äÀÎÀ¸·Î´Â ¹Ì»ý¹°, À½½Ä¹° ¾ÐÀÔ, ºÎÀûÀýÇÑ º¸Á¸ óġ³ª º¸Ã¶¹°, ±¸È£Èí, Ä¡¾ÆÀÇ À§Ä¡ ÀÌ»ó, È­Çй°Áú ȤÀº ¾à¹° º¹¿ëÀÌ ÀÖÀ¸¸ç, Àü½ÅÀûÀÎ ¿äÀÎÀ¸·Î´Â ¿µ¾ç Àå¾Ö, ¾à¸® ÀÛ¿ë, ÀÓ½Å, ´ç´¢, ¾Ë·¯Áö, À¯Àü, Á¤½Å Áúȯ µîÀÌ ÀÖ´Ù. 2. Ä¡ÀºÀÌ Àü¹ÝÀûÀ¸·Î â¹éÇÏ°í ¼¶À¯¼º ¿Ü°üÀ» °¡Áö´Â ¿­±¸ ¸é°ú Ä¡°£ À¯µÎÀÇ ¿°ÁõÀÌ´Ù. Ä¡Àº À¯µÎÀÇ ¼Ò½Ç°ú °°Àº Ä¡ÀºÀÇ ¿ÜÇü º¯È­µµ ÀϾ ¼ö ÀÖ´Ù. À̰ÍÀº ¼ö³â°£ÀÇ ¿°Áõ¼º Ä¡Àº ¼Õ»ó¿¡ ´ëÇÑ ¸¸¼ºÀû ¼øÈ¯Àû º¹±¸ ¹ÝÀÀÀ̸ç Ä¡ÁÖ¿°ÀÇ Æ¯Â¡°ú ¿¬°üµÉ ¶§°¡ ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Abelson murine leukaemia virus A retrovirus belonging to the Type C retrovirus group subfamily (family Oncovirinae) which is associated with leukaemia and produces in vitro transformation of mouse cells.
(05 Mar 2000)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acute granulocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
Origin: Gr. Haima = blood
(27 Sep 1997)
acute leukaemia <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months.
See: acute lymphoblastic leukaemia, acute myeloid leukaemia.
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphoblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting the type of white blood cell known as lymphocytes. Approximately 650 new cases are diagnosed every year in the UK and it is the most common form of childhood leukaemia.
Acronym: ALL
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphocytic leukaemia <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis
(12 Dec 1998)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
acute promyelocytic leukaemia Leukaemia presenting as a severe bleeding disorder, with infiltration of the bone marrow by abnormal promyelocytes and myelocytes, a low plasma fibrinogen, and defective coagulation.
(05 Mar 2000)
adult T-cell leukaemia Lymph nodes show a mixture of small and large atypical cells which are polymorphic and express nuclear pleiomorphism. Adult T-cell leukaemia is caused by HTLV-1 and is rare in the US and Europe but common in Japan. Tumour cells express CD2, CD3, CD5 and lack CD7. The most common chromosome change reported in adult T-cell leukaemia is presence of the 14q + marker
(05 Mar 2000)
aleukaemic leukaemia Leukaemia in which abnormal (or leukaemic) cells are absent in the peripheral blood.
(05 Mar 2000)
avian leukaemia-sarcoma complex A term applied to a group of transmissible virus-induced diseases of chickens causing sarcoma, myeloblastosis, erythroblastosis, leukosis, osteopetrosis, and lymphomatosis. These agents are closely related viruses (avian leukosis-sarcoma virus) causing prolferation of immature erythroid, myeloid, or lymphoid cells, a division of the RNA tumour viruses (subfamily Oncovirinae) causing the avian leukosis-sarcoma complex of diseases; the viruses are subgrouped according to antigenic characteristics and growth in defined types of tissue culture cells.
Synonym: avian erythroblastosis virus, avian leukosis-sarcoma virus, avian lymphomatosis virus, avian myeloblastosis virus, avian sarcoma virus, fowl erythroblastosis virus, fowl lymphomatosis virus, fowl myeloblastosis virus.
(05 Mar 2000)
avian leukaemia virus <virology> Group of C type RNA tumour viruses (Oncovirinae) that cause various leukaemias and other tumours in birds.
The acute leukaemia viruses, that are replication defective and require helper viruses, include avian erythroblastosis (AEV), myeloblastosis (AMV) and myelo cytomatosis viruses.
AEV carries two transforming genes, v erbA and v erbB, the cellular homologue of the latter is the structural gene for the epidermal growth factor receptor. AMV carries v myb and causes a myeloid leukaemia, avian myelocytomatosis virus carries v myc.
The avian lymphatic leukaemia viruses (ALV) are also Retroviridae but are replication competent and induce neoplasia only after several months, they often occur in conjunction with replication defective leukaemia viruses.
(02 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á